NovaBiotics

Executive Summary

NovaBiotics is a UK-based, clinical-stage biotechnology company founded in 2004, operating a dual business model that combines a Pharma division developing first-in-class anti-infectives with a Consumer Health division commercializing personal care products for nail, skin, scalp, and hair health. The company's core technology platform leverages host-directed therapies, particularly cysteamine, to address antimicrobial resistance (AMR) and inflammatory conditions. This approach aims to boost the host's immune response rather than directly targeting pathogens, potentially reducing the risk of resistance development. NovaBiotics' lead pharmaceutical candidates target difficult-to-treat infectious diseases, while its consumer health line provides recurring revenue and brand visibility. The company is headquartered in Aberdeen, UK, and remains privately held, with no disclosed total funding or valuation. As a Phase 1 stage company, NovaBiotics faces typical clinical and regulatory risks but benefits from a differentiated mechanism and dual revenue streams that may de-risk the business model. The growing global focus on AMR and host-directed therapies could provide tailwinds for its pipeline.